Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

INOVIQ and ResearchDx sign USA EXO-NET Services Agreement (ASX:IIQ)

INOVIQ and ResearchDx sign a license and supply agreement for INOVIQ’s EXO-NET® pan-exosome capture product to provide EXO-NET services in the USA ResearchDx Inc is a...read more

Immutep - Appendix 4E & 2023 Full Year Statutory Accounts (ASX:IMM)

To view the Appendix 4E & 2023 Full Year Statutory Accounts, download the attached PDF.

INOVIQ - Appendix 4E and Preliminary Financial Report (ASX:IIQ)

To view the Appendix 4E and Preliminary Financial Report, download the attached PDF.

INOVIQ - EXO-OC Program Completes Serum Equivalence Study (ASX:IIQ)

Serum equivalence study confirms EXO-NET isolates extracellular vesicles (EVs) from both plasma and serum samples- enables access to large ovarian cancer serum biobanks for further research ...read more

Immutep receives positive scientific advice from EMA (ASX:IMM)

SYDNEY, AUSTRALIA – 1 August 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel ...read more

INOVIQ - INOVIQ Investor Briefing (ASX:IIQ)

To view the Investor Briefing, download the attached PDF.

Immutep - Efti clinical data to be presented at ESMO Congress 2023 (ASX:IMM)

-- Mini Oral presentation will include data from TACTI-002 Phase II trial evaluating chemotherapy-free IO combination of efti plus KEYTRUDA® (pembrolizumab) -- Two additional posters on investi...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

Late-stage & registrational trial progress: -- TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational trial in 1st line non-small cell lung cancer (1L NSCLC) ...read more

INOVIQ - Appendix 4C and Quarterly Activities Report - June 2023 (ASX:IIQ)

Highlights: -- Positive clinical data demonstrating SubB2M/CA15-3 test detects all-stages of breast cancer with excellent accuracy (87%), sensitivity (81%) and specificity (93%) -- Post quarter ...read more

Immutep - 1st Patient Dosed in Phase 2 Soft Tissue Sarcoma Trial (ASX:IMM)

SYDNEY, AUSTRALIA – 28 July 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel L...read more

INOVIQ and Promega announce Global Joint Marketing Agreement (ASX:IIQ)

Melbourne, Australia and Madison, WI USA, 6 July 2023: INOVIQ Limited (ASX:IIQ) (INOVIQ), an innovative developer of exosome solutions and precision diagnostics, and Promega Corporation (Promega), a...read more

INOVIQ - SubB2M/CA15.3 Clinical Validation Data Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

Application for quotation of securities - IMM (ASX:IMM)

To view the application, download the attached PDF.

Immutep - US patent granted for Efti with PD-1 pathway inhibitor (ASX:IMM)

SYDNEY, AUSTRALIA – 27 June 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disea...read more

Immutep - US patent granted for Efti with PD-1 pathway inhibitor (ASX:IMM)

Viewing: 91 - 105 of 200 Previous | Next